Following the UK’s departure from the EU, the UK Government has been exploring ways to leverage its new regulatory freedoms. In particular, the life sciences sector has been a key Government priority. As early as January 2021, for example, the Government granted the MHRA powers to fast-track approvals for innovative medicines. More recently, two reports from Westminster bodies have proposed a new regulatory regime for so-called “nutraceuticals” (products that are part drug, part nutritional) to encourage investment.
Oliver Hodgkiss advises clients in the life science sector on transactions at all stages of the product life-cycle. Oliver regularly advises on strategic collaborations, licence agreements and other intellectual property issues that arise during drug development and commercialisation.